Key result
Dipyridamole at 10mg/kg orally demonstrated antiplatelet and antithrombotic activity, with pronounced effects on platelet adhesion in vitro and primary haemostasis in animal models.
Why the study?
Does dipyridamole inhibit platelet function and thrombus formation in preclinical models?
Does dipyridamole inhibit platelet function and thrombus formation in preclinical models?
Dipyridamole demonstrates antiplatelet and antithrombotic activity in preclinical in vitro and in vivo models.
No takes yet. Share an insight, caveat, or question.
Should not alter practice; extends preclinical evidence of antithrombotic activity.
Haarman et al. (1975) studied this question. Dipyridamole was evaluated on Antiplatelet and antithrombotic activity (platelet adhesion, primary haemostasis, thrombus formation). Dipyridamole at 10mg/kg orally demonstrated antiplatelet and antithrombotic activity, with pronounced effects on platelet adhesion in vitro and primary haemostasis in animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: